INT78822

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 1998
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 10
Total Number 14
Disease Relevance 2.35
Pain Relevance 2.29

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (SLURP1) extracellular region (SLURP1) cell adhesion (SLURP1)
Anatomy Link Frequency
SH-SY5Y 1
plasma 1
C cells 1
EPI 1
SLURP1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Angina 7 98.24 Very High Very High Very High
agonist 381 96.24 Very High Very High Very High
adenocard 355 94.52 High High
Opioid 14 92.52 High High
depression 5 89.56 High High
Pain 15 89.08 High High
ischemia 5 88.84 High High
Potency 150 88.52 High High
tolerance 3 78.16 Quite High
addiction 3 77.36 Quite High
Disease Link Frequency Relevance Heat
Neuroblastoma 42 98.76 Very High Very High Very High
Cv General 3 Under Development 5 98.24 Very High Very High Very High
Glioma 2 96.00 Very High Very High Very High
Myocardial Infarction 15 91.72 High High
Hypertension 15 90.88 High High
Depression 5 89.56 High High
Pain 15 89.08 High High
Cv General 4 Under Development 5 88.84 High High
Angina 2 88.28 High High
Reperfusion Injury 5 84.48 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Expressed beta(2)-ARs are functionally coupled to G proteins and display ligand-independent signalling activity, as demonstrated by the ability of an inverse agonist to attenuate basal adenylyl cyclase (AC) activity.
Gene_expression (Expressed) of ARs associated with agonist
1) Confidence 0.43 Published 2000 Journal FEBS Lett. Section Abstract Doc Link 11094159 Disease Relevance 0.34 Pain Relevance 0.61
Improvement in myocardial contractility after the course treatment with the drug was accompanied by reduction in blood plasma levels of ANUP and cGMP.
Gene_expression (levels) of ANUP in plasma
2) Confidence 0.24 Published 1998 Journal Lik. Sprava Section Abstract Doc Link 9844884 Disease Relevance 0.25 Pain Relevance 0.16
This has also been observed for parenteral ARS [18,22], and differs from oral administration, which produces lower and shorter-lived ARS levels.
Gene_expression (produces) of ARS
3) Confidence 0.15 Published 2006 Journal PLoS Medicine Section Body Doc Link PMC1664603 Disease Relevance 0.06 Pain Relevance 0.06
ARS concentrations were still observed 6 h post dosage in some patients in this dataset, suggesting that absorption may have become rate-limiting for ARS clearance.
Gene_expression (clearance) of ARS
4) Confidence 0.13 Published 2006 Journal PLoS Medicine Section Body Doc Link PMC1664603 Disease Relevance 0.06 Pain Relevance 0.07
299 nM), although the selectivity profile was not so satisfactory (Ki values at A1, A2A, A3 ARs of 148, 45, 232 nM, respectively).
Gene_expression (values) of ARs
5) Confidence 0.06 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2583210 Disease Relevance 0.07 Pain Relevance 0.38
For comparison, affinity for the hA1, hA2A, and hA3 ARs stably expressed on CHO cells (A1) or HEK293 cells (A2A, A3) was determined in radioligand binding studies with [3H]DPCPX, [3H]ZM241385 and [125I]I-ABMECA as radioligands, respectively (Table 5).
Gene_expression (expressed) of ARs
6) Confidence 0.05 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2583210 Disease Relevance 0 Pain Relevance 0.18
The compounds were also evaluated in functional assays, measuring their capacity to modulate cAMP levels in CHO cells expressing hA2B ARs.
Gene_expression (expressing) of ARs
7) Confidence 0.05 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2583210 Disease Relevance 0 Pain Relevance 0.09
Competition-binding experiments were performed to evaluate the affinity of the synthesised compounds to hA1, hA2A and hA3 ARs expressed in CHO cells using as radioligands [3H]-CHA, [3H]-CGS 21680 and [125I]-AB-MECA, respectively.
Gene_expression (expressed) of ARs
8) Confidence 0.05 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2583210 Disease Relevance 0 Pain Relevance 0.07
BAY-60–6583, characterised with CHO cells expressing recombinant human A1, A2A or A2B ARs, showed EC50 values for receptor activation >10,000 nM for both A1 and A2A AR and 3 nM for A2B AR subtypes.
Gene_expression (expressing) of ARs
9) Confidence 0.05 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2583210 Disease Relevance 0.83 Pain Relevance 0.26
2A-ARs while in BE(2)-C cells, there is a 60% ?
Gene_expression (while) of ARs in C cells
10) Confidence 0.04 Published 2007 Journal BMC Pharmacol Section Body Doc Link PMC2234403 Disease Relevance 0 Pain Relevance 0
-ARs are present on the same cells lower, more physiologically relevant, concentrations of EPI (300 nM) are able to desensitize the ?
Gene_expression (present) of ARs in EPI
11) Confidence 0.04 Published 2007 Journal BMC Pharmacol Section Body Doc Link PMC2234403 Disease Relevance 0.23 Pain Relevance 0.19
-ARs to prompt ERK1/2 activation in SH-SY5Y cells could explain the lack of GRK3 up-regulation in SH?
Gene_expression (prompt) of ARs in SH-SY5Y
12) Confidence 0.04 Published 2007 Journal BMC Pharmacol Section Body Doc Link PMC2234403 Disease Relevance 0 Pain Relevance 0
In doing so, we hope to determine whether co-expression of the two ARs intrinsically produced this differential ?
Gene_expression (co-expression) of ARs
13) Confidence 0.04 Published 2007 Journal BMC Pharmacol Section Body Doc Link PMC2234403 Disease Relevance 0.15 Pain Relevance 0
-ARs are often co-expressed on the same cell surface.
Gene_expression (co-expressed) of ARs
14) Confidence 0.04 Published 2007 Journal BMC Pharmacol Section Body Doc Link PMC2234403 Disease Relevance 0.36 Pain Relevance 0.21

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox